4395-87-3

Usage

Uses

Used in Pharmaceutical Industry:
4-Isopropylphenylacetonitrile is used as a chemical intermediate for the synthesis of various pharmaceuticals, contributing to the development of new drugs and enhancing the therapeutic potential of existing medications.
Used in Flavor and Fragrance Industry:
As a flavoring agent, 4-Isopropylphenylacetonitrile is employed to impart specific aromatic notes to food products, enriching their sensory profiles and enhancing consumer appeal.
Used in Organic Chemistry Research:
4-Isopropylphenylacetonitrile serves as a valuable compound in organic chemistry research, facilitating the exploration of novel synthetic pathways and the discovery of new chemical entities with potential applications in various fields.

InChI:InChI=1/C11H13N/c1-9(2)11-5-3-10(4-6-11)7-8-12/h3-6,9H,7H2,1-2H3

Upstream product

• 117135-20-3 (4-isopropyl-phenyl)-acetaldehyde-oxime 
• 151-50-8 potassium cyanide 
• 2051-18-5 4-isopropylbenzyl chloride 
• 143-33-9 sodium cyanide 
• 73789-86-3 4-i-propylbenzyl bromide 
• 773837-37-9 sodium cyanide 
• 311-28-4 tetra-(n-butyl)ammonium iodide 
• 99-87-6 4-methylisopropylbenzene 
• 536-60-7 cuminol 

Downstream Products

• 100-21-0 terephthalic acid 
• 501-89-3 4-(carboxymethyl)benzoic acid 
• 14062-21-6 (4-isopropylphenyl)acetic acid ethyl ester 
• 4476-28-2 (4-isopropylphenyl)acetic acid 
• 116435-80-4 (4-isopropyl-phenyl)-acetic acid amide 
• 84558-03-2 2-(4-isopropylphenyl)ethanamine 
• 397-89-7 3c-(4-fluoro-phenyl)-2-(4-isopropyl-phenyl)-acrylonitrile 
• 111412-55-6 3c-(3-chloro-phenyl)-2-(4-isopropyl-phenyl)-acrylonitrile 
• 127581-22-0 γ-cyano-γ-(p-isopropylphenyl)pimelonitrile 
• 52802-59-2 2-Cyano-2-(4-isopropyl-phenyl)-succinic acid diethyl ester 
• 885952-73-8 N-hydroxy-2-(4-isopropyl-phenyl)-acetamidine 
• 10099-57-7 2-(4-isopropylphenyl)ethanol 
• 34177-40-7 p-Isopropylphenylsuccinic acid 
• 106112-20-3 2-(4-isopropylphenyl)propanenitrile 

Relevant academic research and scientific papers

INDOLE DERIVATIVES USEFUL AS PPAR ACTIVATORS

There is provided according to the invention novel compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: (I) useful as PPAR activators.

PREVENTIVE OR THERAPEUTIC AGENT FOR KIDNEY DISEASE

The present invention relates to an agent for the prevention or treatment of a renal disease comprising as an active ingredient a 5-amidino-2-hydroxybenzenesulfonamide derivative represented by the general formula: wherein R1 is a hydrogen atom or an optionally substituted alkyl group; R2 is a dialkylamino group, an alkyl group, a cycloalkyl group, an optionally substituted aryl group etc.; T is an oxygen atom, a sulfur atom etc.; Q is a hydrogen atom or an optionally substituted alkyl group; and Z is a hydrogen atom, a hydroxy group etc., or a pharmaceutically acceptable salt thereof which has an inhibitory effect on mesangial cell proliferation and a decreasing effect on protein excretion in urine, and are useful for preventing or treating of various renal diseases such as IgA nephropathy, diabetic nephropathy, nephritic syndrome and the like.

5-AMIDINO-2-HYDROXYBENZENESULFONAMIDE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME, MEDICINAL USE THEREOF AND INTERMEDIATES IN THE PRODUCTION THEREOF

The present invention relates to a 5-amidino-2-hydroxybenzenesulfonamide derivative represented by the general formula: wherein R1 is an optionally substituted lower alkyl group, an optionally substituted lower alkoxy group, an optionally substituted lower alkenyl group, a cycloalkyl group or a lower acyl group etc.; Q is a hydrogen atom or an optionally substituted lower alkyl group; and Z is a hydrogen atom or a hydroxy group etc., or a pharmaceutically acceptable salt thereof, which exert a potent and selective activated blood coagulation factor X inhibitory activity and is useful as an agent for the prevention or treatment of a disease occurred associating an activated blood coagulation factor X, a pharmaceutical composition comprising the same and an intermediate thereof. These compounds are useful as preventives or remedies for various diseases such as brain infarction, cerebral thrombosis, cerebral embolism, TIA, cerebral vascular jerk, Alzheimer's diseases, myocardial infarction, heart attack, heart failure, thrombosis, pulmonary infarction and pulmonary embolism.

5-AMIDINO-2-HYDROXYBENZENESULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES FOR THEIR PREPARATION

The present invention relates to a 5-amidino-2-hydroxybenzenesulfonamide derivative represented by the general formula: wherein R1 is a hydrogen atom or an optionally substituted lower alkyl group; R2 is a di(lower alkyl)amino group,

Conformational analysis of some 5-substituted 5H-dibenzo[a,d]-cycloheptenes

Conformations and inversion barriers of 5H-dibenzo[a,d]cycloheptene (1a), 5-amino-5H-dibenzo[a,d]cycloheptene (1b), 5-chloro-5H-dibenzo[a,d]cycloheptene (1e), 5-hydroxy-5H-dibenzo[a,d]cycloheptene (1d), 5-methyl-5H-dibenzo[a,d]cycloheptene (1f), N-benzyl-5H-dibenzo[a,d]cyclohepten-5-imine (2) and N-(5H-dibenzo[a,d]cyclohepten-5-yl)benzylideneamine (1c) have been studied by means of dynamic nuclear magnetic resonance spectroscopy (DNMR) techniques, and comparison of the experimentally derived thermodynamic parameters was made with MM3, PM3 and ab initio calculated results. Attempts to determine the inversion barrier of 3-isopropyl-5H-dibenzo[a,d]cyclohepten-5-one (3) failed.

Benzylimidazolines as h5-HT(1B/1D) serotonin receptor ligands: A structure-affinity investigation

Benzylimidazolines may represent a class of 5-HT(1D) ligands that has yet to be exploited. On the basis of a previous report that the 2- (substituted-benzyl)imidazoline α-adrenergic agonist oxymetazoline (8) binds with high affinity at calf brain 5-HT(1D) receptors, we explored the structure-affinity relationships of a series of related derivatives. Each of the aromatic substituents was removed and then reinstated in a systematic manner to determine the influence of the individual substituents on binding. It was found that all of the aromatic substituents of 8 act in concert to impart high affinity. However, although the 3-hydroxy group could be removed without significantly reducing affinity for h5-HT(1D) (i.e., human 5- HT(1Dα)) receptors, this modification reduced h5-HT(1B) (i.e., human 5- HT(1Dβ)) receptor affinity by nearly 50-fold. The 2,6-dimethyl groups also contribute to binding but seem to play a greater role for h5-HT(1B) binding than h5-HT(1D) binding. With the appropriate structural modifications, several compounds were identified that display 20- to > 100-fold selectivity for h5-HT(1D) versus h5-HT(1B) receptors. Preliminary functional data suggest that these compounds behave as agonists. Given that 5-HT(1D) agonists are currently being explored for their antimigraine action and that activation of h5-HT(1B) receptors might be associated with cardiovascular side effects, h5- HT(1D)selective agents may offer a new lead for the development of therapeutically efficacious agents.

Enzymes in organic synthesis 50. Probing the dimensions of the large hydrophobic binding region of the active site of pig liver esterase using substituted aryl malonate substrates

The active side model reported recently for the synthetically useful enzyme pig liver esterase (PLE) permits the structural specificity and stereoselectivity of the enzyme to be interpreted and predicted for a wide range of substrates. The specifications

Perfume compositions as well as perfumed articles and materials containing alkyl substituted benzyl cyanides as a fragrance

Use of one or more alkyl substituted benzyl cyanides having the formula STR1 in which R1 and R2 each may represent a hydrogen atom or a methyl group and R3 represents a branched alkyl group having at most 6 carbon atoms as a perfume component in perfume compositions and in imparting perfume notes to articles for example soaps, cleaning preparations and cosmetic compositions.